Peter Paschka

19.8k citations

93 papers · 6.3k indexed · 1 hit paper · h-index 36

Impact in

Hematology top 0.1%
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
Genetics top 0.2%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research

Papers in ⓘ

Hematology 75
- Acute Myeloid Leukemia Research 58
- Chronic Myeloid Leukemia Treatments 33
Molecular Biology 42
- Protein Degradation and Inhibitors 16
- Histone Deacetylase Inhibitors Research 10

Co-authors: Guido Marcucci (27 shared papers)Clara D. Bloomfield (23 shared papers)Krzysztof Mrózek (23 shared papers)Susan P. Whitman (20 shared papers)Richard A. Larson (22 shared papers)Konstanze Döhner (32 shared papers)Jonathan E. Kolitz (17 shared papers)Andrew J. Carroll (11 shared papers)
Journals: Blood (36 papers)Journal of Clinical Oncology (21 papers)Leukemia (7 papers)Haematologica (4 papers)Hematology (3 papers)
Partner nations: Germany United States Italy

In The Last Decade

Peter Paschka

91 papers receiving 6.2k citations

Hit Papers

align trajectories log scale

IDH1andIDH2Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia WithNPM1Mutation WithoutFLT3Internal Tandem Duplication 2010 · 578 citations

Peers

Countries citing papers authored by Peter Paschka

Since Specialization

Citations

This map shows the geographic impact of Peter Paschka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Peter Paschka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Peter Paschka more than expected).

Fields of papers citing papers by Peter Paschka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Peter Paschka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Peter Paschka. The network helps show where Peter Paschka may publish in the future.

Co-authors

The 25 scholars most cited alongside Peter Paschka, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Peter Paschka Line = papers co-authored together Peter Paschka links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 93 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	IDH1andIDH2Mutations Are Frequent Genetic Alterations in Acute Myeloid Leukemia and Confer Adverse Prognosis in Cytogenetically Normal Acute Myeloid Leukemia WithNPM1Mutation WithoutFLT3Internal Tandem Duplication Journal of Clinical Oncology ·Peter Paschka, Richard F. Schlenk, Verena I. Gaidzik, Marianne Habdank, Jan Krönke, Lars Bullinger, Daniela Späth, Sabine Käyser, Manuela Zucknick, Katharina S. Götze, Heinz-A. Horst, Ulrich Germing, Hartmut Döhner, Konstanze Döhner Hit paper breakdown →	2010	578
2	Adverse Prognostic Significance of KIT Mutations in Adult Acute Myeloid Leukemia With inv(16) and t(8;21): A Cancer and Leukemia Group B Study Journal of Clinical Oncology ·Peter Paschka, Guido Marcucci, Amy S. Ruppert, Krzysztof Mrózek, Hankui Chen, Rick A. Kittles, Tamara Vukosavljevic, Danilo Perrotti, James W. Vardiman, Andrew J. Carroll, Jonathan E. Kolitz, Richard A. Larson, Clara D. Bloomfield	2006	464
3	Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood ·Krzysztof Mrózek, Guido Marcucci, Peter Paschka, Susan P. Whitman, Clara D. Bloomfield	2006	395
4	RUNX1Mutations in Acute Myeloid Leukemia: Results From a Comprehensive Genetic and Clinical Analysis From the AML Study Group Journal of Clinical Oncology ·Verena I. Gaidzik, Lars Bullinger, Richard F. Schlenk, Andreas Zimmermann, Jürgen Röck, Peter Paschka, Andrea Corbacioglu, Jürgen Krauter, Brigitte Schlegelberger, Arnold Ganser, Daniela Späth, Andrea Kündgen, Ingo G.H. Schmidt‐Wolf, Katharina S. Götze, David Nachbaur, Michael Pfreundschuh, Heinz A. Horst, Hartmut Döhner, Konstanze Döhner	2011	328
5	MicroRNA Expression in Cytogenetically Normal Acute Myeloid Leukemia New England Journal of Medicine ·Guido Marcucci, Michael D. Radmacher, Kati Maharry, Krzysztof Mrózek, Amy S. Ruppert, Peter Paschka, Tamara Vukosavljevic, Susan P. Whitman, Claudia D. Baldus, Christian Langer, Chang Gong Liu, Andrew J. Carroll, Bayard L. Powell, Ramiro Garzon, Carlo M. Croce, Jonathan E. Kolitz, Michael A. Caligiuri, Richard A. Larson, Clara D. Bloomfield	2008	314
6	An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia Blood ·Klaus H. Metzeler, Manuela Hummel, Clara D. Bloomfield, Karsten Spiekermann, Jan Braess, Maria‐Cristina Sauerland, Achim Heinecke, Michael D. Radmacher, Guido Marcucci, Susan P. Whitman, Kati Maharry, Peter Paschka, Richard A. Larson, Wolfgang E. Berdel, Thomas Büchner, Bernhard Wörmann, Ulrich Mansmann, Wolfgang Hiddemann, Stefan K. Bohlander, Christian Buske	2008	313
7	Favorable Prognostic Impact of NPM1 Mutations in Older Patients With Cytogenetically Normal De Novo Acute Myeloid Leukemia and Associated Gene- and MicroRNA-Expression Signatures: A Cancer and Leukemia Group B Study Journal of Clinical Oncology ·Heiko Becker, Guido Marcucci, Kati Maharry, Michael D. Radmacher, Krzysztof Mrózek, Dean Margeson, Susan P. Whitman, Yue-Zhong Wu, Sebastian Schwind, Peter Paschka, Bayard L. Powell, Thomas H. Carter, Jonathan E. Kolitz, Meir Wetzler, Andrew J. Carroll, Maria R. Baer, Michael A. Caligiuri, Richard A. Larson, Clara D. Bloomfield	2009	241
8	Prognostic Significance of, and Gene and MicroRNA Expression Signatures Associated With, CEBPA Mutations in Cytogenetically Normal Acute Myeloid Leukemia With High-Risk Molecular Features: A Cancer and Leukemia Group B Study Journal of Clinical Oncology ·Guido Marcucci, Kati Maharry, Michael D. Radmacher, Krzysztof Mrózek, Tamara Vukosavljevic, Peter Paschka, Susan P. Whitman, Christian Langer, Claudia D. Baldus, Chang‐Gong Liu, Amy S. Ruppert, Bayard L. Powell, Andrew J. Carroll, Michael A. Caligiuri, Jonathan E. Kolitz, Richard A. Larson, Clara D. Bloomfield	2008	224
9	Response and resistance in 300 patients with BCR‐ABL–positive leukemias treated with imatinib in a single center Cancer ·Tanja Lahaye, Birte Riehm, Ute Berger, Peter Paschka, Martin C. Müller, Sebastian Kreil, Kirsten Merx, Uwe Schwindel, Claudia Schoch, Rüdiger Hehlmann, Andreas Hochhaus	2005	191
10	FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications Blood ·Susan P. Whitman, Amy S. Ruppert, Michael D. Radmacher, Krzysztof Mrózek, Peter Paschka, Christian Langer, Claudia D. Baldus, Jing Wen, Frederick Racke, Bayard L. Powell, Jonathan E. Kolitz, Richard A. Larson, Michael A. Caligiuri, Guido Marcucci, Clara D. Bloomfield	2007	188
11	Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development Leukemia ·Andreas Burchert, Ying Wang, Dawei Cai, Nikolas von Bubnoff, Peter Paschka, Sabine Müller‐Brüsselbach, Oliver G. Ottmann, Justus Duyster, Andreas Hochhaus, Andreas Neubauer	2005	181
12	Clonal evolution in relapsed NPM1-mutated acute myeloid leukemia Blood ·Jan Krönke, Lars Bullinger, Veronica Teleanu, Florian Tschürtz, Verena I. Gaidzik, Michael W.M. Kühn, Frank G. Rücker, Karlheinz Holzmann, Peter Paschka, Silke Kapp-Schwörer, Daniela Späth, Thomas Kindler, Marcus M. Schittenhelm, Jürgen Krauter, Arnold Ganser, Gudrun Göhring, Brigitte Schlegelberger, Richard F. Schlenk, Hartmut Döhner, Konstanze Döhner	2013	181
13	Lack of clinical efficacy of imatinib in metastatic melanoma British Journal of Cancer ·Selma Ugurel, Ralf Hildenbrand, A Zimpfer, Paul La Rosée, Peter Paschka, Antje Sucker, Petra Keikavoussi, Jürgen C. Becker, Werner Rittgen, Andreas Hochhaus, Dirk Schadendorf	2005	180
14	Wilms’ Tumor 1 Gene Mutations Independently Predict Poor Outcome in Adults With Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study Journal of Clinical Oncology ·Peter Paschka, Guido Marcucci, Amy S. Ruppert, Susan P. Whitman, Krzysztof Mrózek, Kati Maharry, Christian Langer, Claudia D. Baldus, Weiqiang Zhao, Bayard L. Powell, Maria R. Baer, Andrew J. Carroll, Michael A. Caligiuri, Jonathan E. Kolitz, Richard A. Larson, Clara D. Bloomfield	2008	170
15	Precision oncology for acute myeloid leukemia using a knowledge bank approach Nature Genetics ·Moritz Gerstung, Elli Papaemmanuil, Sancha Martin, Lars Bullinger, Verena I. Gaidzik, Peter Paschka, Michael Heuser, Felicitas Thol, Niccolò Bolli, Peter Ganly, Arnold Ganser, Ultan McDermott, Konstanze Döhner, Richard F. Schlenk, Hartmut Döhner, Peter J. Campbell	2017	161
16	TET2 Mutations in Acute Myeloid Leukemia (AML): Results From a Comprehensive Genetic and Clinical Analysis of the AML Study Group Journal of Clinical Oncology ·Verena I. Gaidzik, Peter Paschka, Daniela Späth, Marianne Habdank, Claus‐Henning Köhne, Ulrich Germing, Marie von Lilienfeld‐Toal, Gerhard Held, Heinz‐August Horst, Detlef Haase, Martin Bentz, Katharina S. Götze, Hartmut Döhner, Richard F. Schlenk, Lars Bullinger, Konstanze Döhner	2012	141
17	High Expression Levels of the ETS-Related Gene, ERG, Predict Adverse Outcome and Improve Molecular Risk-Based Classification of Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study Journal of Clinical Oncology ·Guido Marcucci, Kati Maharry, Susan P. Whitman, Tamara Vukosavljevic, Peter Paschka, Christian Langer, Krzysztof Mrózek, Claudia D. Baldus, Andrew J. Carroll, Bayard L. Powell, Jonathan E. Kolitz, Richard A. Larson, Clara D. Bloomfield	2007	140
18	High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene-expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study Blood ·Christian Langer, Michael D. Radmacher, Amy S. Ruppert, Susan P. Whitman, Peter Paschka, Krzysztof Mrózek, Claudia D. Baldus, Tamara Vukosavljevic, Chang‐Gong Liu, Mary Elizabeth Ross, Bayard L. Powell, Albert de la Chapelle, Jonathan E. Kolitz, Richard A. Larson, Guido Marcucci, Clara D. Bloomfield	2008	127
19	Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon α Leukemia ·Kirsten Merx, M. C. Muller, Sebastian Kreil, Tanja Lahaye, Peter Paschka, Claudia Schoch, A Weißer, Christian Kühn, Ursula Berger, Harald Gschaidmeier, Rüdiger Hehlmann, Andreas Hochhaus	2002	124
20	Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing Blood ·Anna Dolnik, Julia C. Engelmann, Maren Scharfenberger‐Schmeer, Julian Mauch, Sabine Kelkenberg-Schade, Berit Haldemann, Tamara Fries, Jan Krönke, Michael W.M. Kühn, Peter Paschka, Sabine Käyser, Stephan Wolf, Verena I. Gaidzik, Richard F. Schlenk, Frank G. Rücker, Hartmut Döhner, Claudio Lottaz, Konstanze Döhner, Lars Bullinger	2012	112

About Peter Paschka

Peter Paschka is a scholar working on Hematology, Molecular Biology, Genetics, Immunology and Public Health, Environmental and Occupational Health, having authored 93 papers that have together received 6.3k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (58 papers), Chronic Myeloid Leukemia Treatments (33 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (21 papers), Chronic Lymphocytic Leukemia Research (17 papers), Protein Degradation and Inhibitors (16 papers), Acute Lymphoblastic Leukemia research (11 papers), Histone Deacetylase Inhibitors Research (10 papers) and Eosinophilic Disorders and Syndromes (8 papers). The work is most often cited by research in Hematology (4.6k citations), Genetics (2.0k citations), Cancer Research (1.4k citations), Molecular Biology (3.3k citations) and Public Health, Environmental and Occupational Health (932 citations). Peter Paschka has collaborated with scholars based in Germany, United States and Italy. Frequent co-authors include Guido Marcucci, Clara D. Bloomfield, Krzysztof Mrózek, Susan P. Whitman, Richard A. Larson, Konstanze Döhner, Jonathan E. Kolitz, Andrew J. Carroll, Hartmut Döhner and Lars Bullinger. Their work appears in journals such as Blood, Journal of Clinical Oncology, Leukemia, Haematologica and Hematology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact